Abstract
Development of acquired resistance against antiestrogen treatment is a serious problem in human breast cancer, and knowledge of alterations resulting in resistance is important for selection of further treatment. To mimic the clinical situation we have established a series of MCF-7 human breast cancer cell lines by long term treatment with the antiestrogens tamoxifen, ICI 164,384, and ICI 182,780. Common for these cell lines is a decreased expression of the estrogen receptor α(ERα). In human breast cancer, lack of response to endocrine therapy is often associated with decreased expression of the estrogen receptor and increased expression of epidermal growth factor receptor (EGFR) and/or HER-2/neu (ErbB-2). Our antiestrogen resistant cell lines did not express altered levels of EGFR, HER-2/neu, ErbB-3, or ErbB-4. Estrogen and antiestrogen regulation of HER-2/neu expression was essentially similar in parent and resistant MCF-7 cells. Treatment with antibodies to HER-2/neu (HerceptinTM) did not affect growth of MCF-7 cells or resistant cells, indicating that in this in vitro model system, acquired antiestrogen resistance does not emerge from activation of the HER-2/neu signaling pathway. In MCF-7 cells transfected with HER-2/neu and/or ErbB-3, overexpression alone did not result in resistance. However, addition of heregulinl-β1 abolished the inhibitory activity of ICI 182,780 on both vector and HER-2/neu/ErbB-3 transfected MCF-7 cells, demonstrating that activation of the HER-2/neu receptor signaling pathway can override the growth inhibitory effect of ICI 182,780.
Similar content being viewed by others
References
Rajkumar T, Gullick WJ: The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 29: 3–9, 1994
Carpenter G, Cohen S: Epidermal growth factor. Annu Rev Biochem 48: 1979
Coussens L, Yang FT, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132–1139, 1985
King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974–976, 1985
Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, neubauer MG, Shoyab, M: Ligand-specific activation of HER4/pl80erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746–1750, 1993
Kraus MH, Fedi P, Starks V, Muraro R, Aaronson SA: Demonstration of liganddependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci USA 90: 2900–2904, 1993
Carraway KL, Cantley LC: A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78: 5–8, 1994
Sainsbury JR, Farndon JR, Sherbet GV, Harris AL: Epidermalgrowth-factor receptors and oestrogen receptors in human breast cancer. Lancet i: 364–366, 1985
Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol.Endocrinol 1: 216–223, 1987
Klijn JG, Look MP, Portengen H, Alexieva FJ, van PW, Foekens JA: The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 29: 73–83, 1994
Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermalgrowth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i: 1398–1402, 1987
Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C: Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 34: 123–131, 1989
Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW: Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29: 117–125, 1994
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177–182, 1987
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707–712, 1989
Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH: Relationship between cerbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118–121, 1992
Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137–144, 1994
Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791–808, 1998
Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193–9197, 1989
Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC: Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66: 1116–1121, 1992
Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW, Ellis IO: C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 74: 229–233, 1996
Vogt U, Bielawski K, Schlotter, CM, Bosse U, Falkiewicz, B, Podhajska AJ: Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene 233: 375–380, 1998
Lykkesfeldt AE, Sørensen EK: Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol 31: 131–138, 1992
Lykkesfeldt AE, Madsen MW, Briand P: Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMRR-1. Cancer Res 54: 1587–1595, 1994
Lykkesfeldt AE, Larsen SS, Briand P: Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 61: 529–534, 1995
Larsen SS, Madsen MW, Jensen BL, Lykkesfeldt AE: Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int J Cancer 72: 1129–1136, 1997
Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE: Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57: 585–589, 1997
Osborne CK, Fuqua SA: Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 32: 49–55, 1994
Lykkesfeldt AE: Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol 35 (Suppl 5) 1996
Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, Melnerney EM: William L.McGuire Mcmorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 44: 23–38, 1997
Johnston SR: Acquired tamoxifen resistance in human breast cancer- potential mechanisms and clinical implications. Anticancer Drugs 8: 911–930, 1997
Miller DL, El-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG: Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 5: 1263–1274, 1994
Van Agthoven TT, van Agthoven TL, Portengen H, Foekens JA, Dorssers, LC: Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52: 5082–5088, 1992
Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85–95, 1992
Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C: The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer ResTreat 38: 57–66, 1996
Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435–2446, 1995
Briand P, Lykkesfeldt AE: Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res 44: 1114–1119, 1984
Egeblad M, Jäättelä M: Overexpression of ErbB receptor tyrosine kinases does not protect against TNF-induced apoptosis or starvation in MCF-7 breast carcinoma cells (submitted).
Madsen MW, Lykkesfeldt AE, Laursen I, Nielsen KV, Briand P: Altered gene expression of c-myc, epidermal growth factor receptor, transforming growth factor-alpha, and c-erb-B2 in an immortalized human breast epithelial cell line, HMT-3522, is associated with decreased growth factor requirements. Cancer Res 52: 1210–1217, 1992
Krainer AR, Maniatis T, Ruskin B, Green MR: Normal and mutant human betaglobin pre-mRNAs are faithfully and efficiently spliced in vitro. Cell 36: 993–1005, 1984
Laborda J: 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 19: 3998–3998, 1991
Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6: 605–610, 1987
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WT, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185(HER2) antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289, 1992
Kumar R, Shepard HM, Mendelsohn J: Regulation of phosphorylation of the cerbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol 11: 979–986, 1991
Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM: Differential responses of human tumor cell lines to anti-p185(HER2) monoclonal antibodies. Cancer Immunol. Immunother 37: 255–263, 1993
Di Fiore PP, Segatto O, Taylor WG, Aaronson SA, Pierce JH: EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science 248: 79–83, 1990
Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R: Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56: 3350–3358, 1996
Freiss G, Prebois C, Vignon F: William L. McGuire Memorial Symposium. Control of breast cancer cell growth by steroids and growth factors: interactions and mechanisms. Breast Cancer Res Treat 27: 57–68, 1993
Sainsbury JR, Farndon JR, Harris AL, Sherbet GV: Epidermal growth factor receptors on human breast cancers. Br J Surg 72: 186–188, 1985
Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216–223, 1987
Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C: Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 34: 123–131, 1989
Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Farndon JR, Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i: 182–185, 1989
Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259–1266, 1995
Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'sullivan J, Martino S, Osborne CK: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4: 7–12, 1998
Berthois Y, Dong XF, Martin PM: Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. Biochem Biophys Res Commun 159: 126–131, 1989
Yarden RI, Lauber AH, El AD, Chrysogelos SA: Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. Endocrinology 137: 2739–2747, 1996
Sepp LL, Eberhard I, Ma Z, Cho C, Serve H, Liu F, Rosen N, Lupu R: Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene 12: 1679–1687, 1996
Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, Shepard HM, Kuang WL, Wood WI, Goeddel DV, Vandlen RL: Identification of heregulin, a specific activator of pl85erbB2. Science 256: 1205–1210, 1992
Newby JC, Johnston SR, Smith IF, Dowsett M: Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643–1651, 1997
Russell KS, Hung MC: Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52: 6624–6629, 1992
Read LD, Keith D, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947–3951, 1990
Antoniotti S, Maggiora P, Dati C, DeBortoli M: Tamoxifen upregulates c-erbB2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28: 318–321, 1992
Dati C, Antoniotti S, Taverna D, Perroteau I, DeBortoli M: Inhibition of c-erbB 2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5: 1001–1006, 1990
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin(TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825–2831, 1998
Witters LM, Kumar R, Chinchilli VM, Lipton A: Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42: 1–5, 1997
Liu Y, El-Ashry D, Chen D, Ding IY, Kern FG: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifensensitivity in vivo. Breast Cancer Res Treat 34: 97–117, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Larsen, S.S., Egeblad, M., Jäättelä, M. et al. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. Breast Cancer Res Treat 58, 41–56 (1999). https://doi.org/10.1023/A:1006232830161
Issue Date:
DOI: https://doi.org/10.1023/A:1006232830161